Phase III, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Have Been Previously Exposed to TNF Inhibitors
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms HICKORY
- Sponsors Roche
- 24 Apr 2019 Planned End Date changed from 26 Dec 2020 to 17 Jul 2020.
- 24 Apr 2019 Planned primary completion date changed from 26 Dec 2020 to 24 Apr 2020.
- 11 Feb 2019 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History